Testing an Educational Tool for Melanoma Patients With Autoimmune Disease
Tests an educational tool for adults with melanoma and autoimmune disease considering immunotherapy.
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- Status
- Recruiting
- People taking part
- 125 people, planned
- Started
- 20 Apr 2022
- Expected to end
- 2 Feb 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- Best Practice
- Educational Intervention
- Interview
- Questionnaire Administration
- Survey Administration
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma and an autoimmune disease who are deciding about, or already use, immune checkpoint inhibitor drugs. They will give opinions on an educational tool. Doctors who treat melanoma at MD Anderson can also join.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma together with an autoimmune disease: inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, systemic lupus erythematosus, psoriasis, or a spondyloarthropathy (ankylosing spondylitis, reactive arthritis, psoriatic arthritis, enteropathic arthritis or spondylitis). The autoimmune disease must be diagnosed by a specialist doctor.
- Earlier treatment
- For the autoimmune disease, treatment with disease-specific medicines is asked for, for example aminosalicylates, corticosteroids, methotrexate, sulfasalazine or targeted therapy. The doctor has advised starting an immune checkpoint inhibitor, or the person is taking one or has already decided whether to start.
Main reasons for not taking part
- No e-mail access and computer with Internet access or telephone
- Cannot communicate in English or Spanish
- Under 18 years old
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosis of melanoma
- Diagnosis of pre-existing autoimmune disease; Inflammatory bowel disease; Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist; For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically; Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists); Rheumatoid arthritis; Diagnosis of rheumatoid arthritis by a rheumatologist; Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy; Systemic lupus erythematosus; Diagnosis of systemic lupus erythematosus by a rheumatologist; Psoriasis; Diagnosis of psoriasis by a dermatologist; Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies; Spondyloarthropathies; Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis/spondylitis by a rheumatologist; Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy
- Age of 18 years or older
- Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor
- E-mail access and computer with Internet access or telephone
- Ability to communicate in English or Spanish
- CLINICIAN
- Prescribed immune checkpoint inhibitors
- Are providing care for patients with melanoma
- In the clinics at MD Anderson
Where in United States
- M D Anderson Cancer CenterHouston, United StatesContact: Maria A. Lopez-OlivoTaking people
About the trial
What the trial wants to find out
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
The 3 groups in the trial
- Part A (Interview)
Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
Treatment: Educational Intervention and Interview
- Part B Group I (standard information)
Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Treatment: Best Practice, Questionnaire Administration, and Survey Administration
- Part B Group II (educational tool)
Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Treatment: Educational Intervention, Questionnaire Administration, and Survey Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers
- Plain-language title
- Testing an Educational Tool for Melanoma Patients With Autoimmune DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026